Treatment with the highest dose of investigational injectable amycretin -- a unimolecular GLP-1 and amylin receptor agonist -- yielded a 22% weight loss after 36 weeks in a phase Ib/IIa trial, said ...

A new study uncovers a novel mechanism through which brown fat is transformed into heat, offering protection against obesity-related diseases. Obesity affects 650 million people worldwide and signific ...

This means that exclusively surgical treatment cannot be applied without interdisciplinary evaluation. Along the same lines, ...

The extent to which newer, incretin-based drugs for obesity improve disease outcomes via weight loss versus the direct ...

A recent study published in Cell reveals that the repeated DNA sequence that leads to Huntington’s disease (HD) expands ...

A study of nearly 1,000 people with post-COVID-19 syndrome (PCS) revealed that two-thirds still experienced significant symptoms, including reduced exercise capacity and cognitive performance, two ...

A study published in December 2024 demonstrates how natural language processing techniques, combined with dedicated human ...

Gut microbiota plays a critical role in childhood obesity by influencing energy metabolism, inflammation, and appetite ...

New Anglo/U.S. obesity and cardiometabolic specialist Verdiva Bio Ltd. has launched with a massive $411 million series A and a portfolio of GLP-1 and amylin agonists in-licensed from China.

Nonalcoholic fatty liver disease (NAFLD) affects up to 40% of the population in western countries and is one of the most ...

The Arkansas Integrative Metabolic Research Center will host Jeffrey Rathmell, a professor of pathology, microbiology and immunology from Vanderbilt University on Wednesday, Jan. 22.

Announcing a new article publication for Cardiovascular Innovations and Applications journal. Many studies have reported that obesity causes heart failure (HF) pathogenesis. The elevated circulating ...